Vaccines 2013, 1(4), 513-526; doi:10.3390/vaccines1040513

What Has 30 Years of HIV Vaccine Research Taught Us?

Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA
Received: 21 August 2013; in revised form: 14 October 2013 / Accepted: 17 October 2013 / Published: 30 October 2013
(This article belongs to the Special Issue HIV Vaccines)
PDF Full-text Download PDF Full-Text [363 KB, uploaded 30 October 2013 14:56 CET]
Abstract: When HIV was discovered and established as the cause of AIDS in 1983–1984, many people believed that a vaccine would be rapidly developed. However, 30 years have passed and we are still struggling to develop an elusive vaccine. In trying to achieve that goal, different scientific paradigms have been explored. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. Major lessons learned are: the development of an HIV vaccine is an extremely difficult challenge; the temptation of just following the fashion should be avoided; clinical trials are critical, especially large-scale efficacy trials; HIV vaccine research will require long-term commitment; and sustainable collaborations are needed to accelerate the development of an HIV vaccine. Concrete actions must be implemented with the sense of urgency imposed by the severity of the AIDS epidemic.
Keywords: HIV vaccines; lessons learned; clinical trials; HIV; AIDS

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Esparza, J. What Has 30 Years of HIV Vaccine Research Taught Us? Vaccines 2013, 1, 513-526.

AMA Style

Esparza J. What Has 30 Years of HIV Vaccine Research Taught Us? Vaccines. 2013; 1(4):513-526.

Chicago/Turabian Style

Esparza, José. 2013. "What Has 30 Years of HIV Vaccine Research Taught Us?" Vaccines 1, no. 4: 513-526.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert